Acorda Therapeutics, Inc.
ACOR · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $118 | $119 | $129 | $153 |
| % Growth | -0.8% | -8.1% | -15.6% | – |
| Cost of Goods Sold | $46 | $30 | $41 | $34 |
| Gross Profit | $72 | $88 | $88 | $119 |
| % Margin | 60.9% | 74.4% | 68.4% | 78.1% |
| R&D Expenses | $5 | $6 | $10 | $23 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $90 | $106 | $124 | $153 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $18 | $31 | $31 |
| Operating Expenses | $95 | $130 | $166 | $206 |
| Operating Income | -$23 | -$42 | -$77 | -$87 |
| % Margin | -19.8% | -35.5% | -59.9% | -56.8% |
| Other Income/Exp. Net | -$273 | $7 | -$15 | -$1 |
| Pre-Tax Income | -$296 | -$35 | -$109 | -$108 |
| Tax Expense | -$43 | $31 | -$5 | -$8 |
| Net Income | -$253 | -$66 | -$104 | -$100 |
| % Margin | -215% | -55.6% | -80.5% | -65.1% |
| EPS | -203.59 | -66.9 | -195.75 | -246.4 |
| % Growth | -204.3% | 65.8% | 20.6% | – |
| EPS Diluted | -203.59 | -66.9 | -195.75 | -246.4 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $0 | $1 |
| Interest Expense | $32 | $28 | $30 | $31 |
| Depreciation & Amortization | $32 | $32 | $33 | $22 |
| EBITDA | -$202 | -$10 | -$45 | -$65 |
| % Margin | -171.6% | -8.5% | -34.7% | -42.5% |